Cargando…
A High-Throughput Clinical Laboratory Methodology for the Therapeutic Monitoring of Ibrutinib and Dihydrodiol Ibrutinib
Ibrutinib (IBR) is an oral anticancer medication that inhibits Bruton tyrosine kinase irreversibly. Due to the high risk of adverse effects and its pharmacokinetic variability, the safe and effective use of IBR is expected to be facilitated by precision dosing. Delivering suitable clinical laborator...
Autores principales: | Karvaly, Gellért Balázs, Vincze, István, Balogh, Alexandra, Köllő, Zoltán, Bödör, Csaba, Vásárhelyi, Barna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9331678/ https://www.ncbi.nlm.nih.gov/pubmed/35897942 http://dx.doi.org/10.3390/molecules27154766 |
Ejemplares similares
-
Therapeutic Monitoring of Orally Administered, Small-Molecule Anticancer Medications with Tumor-Specific Cellular Protein Targets in Peripheral Fluid Spaces—A Review
por: Köllő, Zoltán, et al.
Publicado: (2023) -
Sensitive, High-Throughput Liquid Chromatography-Tandem Mass Spectrometry Analysis of Atorvastatin and Its Pharmacologically Active Metabolites in Serum for Supporting Precision Pharmacotherapy
por: Karvaly, Gellért Balázs, et al.
Publicado: (2021) -
Development of a methodology to make individual estimates of the precision of liquid chromatography-tandem mass spectrometry drug assay results for use in population pharmacokinetic modeling and the optimization of dosage regimens
por: Karvaly, Gellért Balázs, et al.
Publicado: (2020) -
A pharmacokinetics‐based approach to the monitoring of patient adherence to atorvastatin therapy
por: Karvaly, Gellért Balázs, et al.
Publicado: (2021) -
Ibrutinib-induced cardiomyopathy
por: Kyi, Htay Htay, et al.
Publicado: (2019)